Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Topics
  4. Therapeutic Focus
  5. Digital Health

Digital Health

Thumbnail
August 30, 2022

ESC 2022 – Preventicus gets halfway there

Improving atrial fibrillation diagnosis is one thing; improving outcomes another.

Thumbnail
August 18, 2022

Better Therapeutics banks on data and partnerships

But difficulties around reimbursement, selling and market value could make it hard for the app maker to live up to its name.

Article image
Vantage logo
August 12, 2022

Trad device start-ups catch the cash

Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.

Article image
Vantage logo
June 15, 2022

To back, or back away from, digital health?

Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.

Article image
Vantage logo
May 20, 2022

Pfizer and its Sidekick snare a new approval

Article image
Vantage logo
April 08, 2022

Viz AI passes the $1bn valuation mark

Article image
Vantage logo
January 26, 2022

Akili plays the Spac game for $1bn

But, judging by similar transactions, the valuation might not stay that high for long.

Article image
Vantage logo
January 24, 2022

Watson, Watsoff

Article image
Vantage logo
October 22, 2021

23andme's latest deal leaves a sour taste

Article image
Vantage logo
September 29, 2021

Akili and Shionogi find the clinical game hard to play

Article image
Vantage logo
July 09, 2021

Medtech venture funding hits new heights

Private device makers enjoy the biggest quarter for four years – and the average deal is larger than ever.

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up